SCHEMBL1962537

SCHEMBL1962537

CCc1c(-c2nnc(NCc3cccc(OC)c3)o2)ccc(O)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CB P42338 2/20 0.47
▸ MTNR1A P48039 1/20 0.41
▸ MTNR1B P49286 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ MAPK11 Q15759 1/20 0.40
▸ MAPK14 Q16539 1/20 0.40
▸ PIK3CG P48736 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ PDCD1 Q15116 2/20 0.39
▸ CD274 Q9NZQ7 2/20 0.39
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1551968 0.86 CDC7 (0.52) PDCD1CD274CDC7CCNE1CDK2
SCHEMBL12550860 0.85 CDC7 (0.47) PDCD1CD274CDC7CCNE1CDK2
SCHEMBL1961463 0.81 MAPT (0.40) PIK3CBKDM4EPDCD1CD274MAPT
SCHEMBL12550864 0.76 CDC7 (0.53) KDM4EPDCD1CD274TP53ALDH1A1
SCHEMBL1557178 0.71 CDC7 (0.74) CDC7CCNE1CDK2DBF4
SCHEMBL2189331 0.70 CDC7 (0.47) MTNR1AMTNR1BMAPTKMT2AMEN1
SCHEMBL2190120 0.70 CDC7 (0.47) MTNR1AMTNR1BMAPTKMT2AMEN1
SCHEMBL7955873 0.69 CDK2 (0.55) POLBMAPTTP53CDC7CCNE1
SCHEMBL1960827 0.68 CDC7 (0.57) POLBPDCD1CD274TP53CDC7
SCHEMBL1551977 0.67 KDM4E (0.41) KDM4EMAPTKMT2AMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2313380-B1 OXADIAZOLE DERIVATIVES FOR TREATING DIABETES MERCK PATENT GMBH (DE) 2013-12-11 — — EP claimed
US-8377975-B2 Oxadiazole derivatives for the treatment of diabetes MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-02-19 — — US claimed
US-20110139654-A1 OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT (DE) 2011-06-16 — — US claimed
US-8377975-B2 Oxadiazole derivatives for the treatment of diabetes MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-02-19 — — US disclosed
US-8377975-B2 Oxadiazole derivatives for the treatment of diabetes MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-02-19 — — US disclosed
US-20110139654-A1 OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT (DE) 2011-06-16 — — US disclosed
US-20110139654-A1 OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES MERCK PATENT GESELLSCHAFT (DE) 2011-06-16 — — US disclosed
WO-2010020305-A1 OXADIAZOLE DERIVATIVES FOR TREATING DIABETES MERCK PATENT GMBH (DE) 2010-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110139654-A1 OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES PFKL, RXFP3, OXA1L PIK3CB 1367/4885MTNR1A 2203/4885MTNR1B 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback